US Prenatal Genetic Testing Market to Take the Big Leap Partnering with Big Data Companies

USA - English

• India - English

SANTA CLARA, Calif., Sept. 12, 2017 /PRNewswire/ -- The United States (U.S.) prenatal genetic testing market is experiencing accelerated growth, with industry disruptions and lifestyle changes creating novel revenue opportunities. Factors stimulating growth include demand for prenatal genetic tests due to enhanced assay outcomes through non-invasive methodologies and a growing number of women choosing to become pregnant at an advanced maternal age. High demand has led to a significant level of merger and acquisition activity and numerous collaborations, which have bolstered the product portfolio of several companies in the women's healthcare segment.

Frost & Sullivan's research, Growth Opportunities in the US Prenatal Genetic Testing Market, Forecast to 2021, finds that the market is expected to reach $2.45 billion by 2021 and register a compound annual growth rate of 10.1 percent from 2016 to 2021. The analysis identifies current and expected market developments; drivers and restraints; mergers and acquisitions; competitive dynamics; and revenue forecasts across four segments, namely non-invasive pregnancy testing, carrier screening for cystic fibrosis, invasive testing, and miscarriage tests. It also discusses the impact of Protecting Access to Medicare Act (PAMA) and the laboratory-developed test (LDT) guidelines issued by the Food and Drug Administration.

To access more information on this analysis, please click here.

"Companies are exploring new avenues to market their products, thereby strategically tying up with in vitro fertilization (IVF) clinics, physicians, and obstetrician-gynecologists (OBGYNs). New business models like direct-to-consumer (DTC) are seeing increased uptake due to ease of use and hassle-free processing," said Transformational Health Senior Industry Analyst Supratik Paul. "Partnerships with big data companies will be the next big leap in the prenatal genetic testing market, thereby providing interpretation of vast volumes of data to increase specificity and sensitivity."

Strategic imperatives for prenatal genetic test providers include:

• Investing in research and development to reduce test failure rates and improve company differentiator rates;
• Strategizing about test prices to avoid revenue loss following the standardization of prenatal test prices in January 2018;
• Diversifying product portfolios to address a broad segment of genetic tests for women's healthcare, along with competitive pricing and enhanced accuracy; and
• Leveraging marketing opportunities and exploring new marketing areas such as advertising through genetic counselors, physicians and OBGYNs, as well as embracing social media and IVF centers.

"Companies are shifting toward online and retail-like business models such as DTC to promote the use of tests. Such DTC companies can stifle the growth of expensive, physician-prescribed LDT tests as there will be a higher preference toward low-cost options," noted Paul. "In addition, approximately 60 to 65 percent of the prenatal genetic tests are now switching to next-generation sequencing (NGS) methodologies. Transitioning to NGS-based workflows from microarray will open up opportunities to create tests with better specificity, sensitivity and cost."

Growth Opportunities in the US Prenatal Genetic Testing Market, Forecast to 2021 is part of Frost & Sullivan's Life Sciences Growth Partnership Service program.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

Growth Opportunities in the US Prenatal Genetic Testing Market, Forecast to 2021
K1C4-55

Contact:
Mariana Fernandez
Corporate Communications – North America
P: +54 (11) 4778.3540
E: [email protected]

http://ww2.frost.com
twitter: @FS_Healthcare
LinkedIn: Transform Health

SOURCE Frost & Sullivan

Related Links

http://www.frost.com